BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,
Briacell Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.03%. The profit margin, also known as the revenue ratio or gross profit ...
BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga ...
BriaCell (BCTX) Therapeutics announces that the Data Safety Monitoring Board has completed its first review of safety events in patients enrolled in BriaCell’s pivotal randomized Phase 3 study ...
Short interest in BriaCell Therapeutics Corp (NASDAQ:BCTX) decreased during the last reporting period, falling from 745.07K to 534.83K. This put 1.66% of the company's publicly available shares ...
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in ...
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel ...
SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast ...
Equities researchers at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback